Previous 10 |
Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Jan. 4, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically...
Nuvalent (NASDAQ:NUVL): Q3 GAAP EPS of -$0.39 misses by $0.14. Cash, cash equivalents and marketable securities were $302.4 million as of September 30, 2021 Press Release For further details see: Nuvalent EPS misses by $0.14
Nuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results ARROS-1 Clinical Trial of NVL-520 for the Treatment of Patients with Advanced ROS1-positive NSCLC and Other Solid Tumors is Open for Enrollment Company On-track for Initiation of Clinical Trial of NV...
New Preclinical Data Supports Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC Nuvalent to present at AACR-NCI-EORTC Molecular Targets Conference Data provided further evidence that NVL-520 and NVL-655 selectively inhibited ROS1 and ALK compared to TRKB, were brai...
A record 62 recent IPOs joined the Russell 2000 small-cap index this month. Here's a look at some of the biotech stocks that just joined: Lyell Immunopharma Lyell Immunopharma (NASDAQ:LYEL), which is developing T cell therapies for solid tumors, had a 25M-share IPO in June expected to net pro...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks flip-flopped between gains and losses Friday to end a volatile week on Wall Street, as investors appeared content to consolidate posit...
News, Short Squeeze, Breakout and More Instantly...
Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor PR Newswire CAMBRIDGE, Mass. , July 22, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company foc...
Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024 PR Newswire CAMBRIDGE, Mass. , July 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharma...
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer PR Newswire CAMBRIDGE, Mass. , July 11, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely target...